

# EP-624

## "Levels of AGEs (advanced glycation end products), sRAGE (AGE's receptor) and their relationship with cardiovascular risk factors in newly diagnosed type 2 diabetic patients"

**Ma. Etzabel Villegas Rodríguez<sup>1</sup>, Sergio Eduardo Solorio Meza<sup>2</sup>, Martha Eugenia Fajardo<sup>1</sup>, Jaime Uribarri<sup>3</sup>, JM Malacara<sup>1</sup>, Sofia Torres Graciano<sup>1</sup>, Ma. Eugenia Garay- Sevilla<sup>1</sup>.**

<sup>1</sup>Department of Medical Science, University of Guanajuato. Campus León, México. <sup>2</sup>Instituto Mexicano del Seguro Social. México

<sup>3</sup>Department of Medicine. The Mount Sinai Health System. Incahn School of Medicine at Mount Sinai.

### INTRODUCTION

Diabetes is associated with a greatly increased risk of cardiovascular disease and the advanced glycation end products (AGEs) and their receptors play an important role in these complications [1, 2, 3]. Detection of subclinical or preclinical atherosclerosis can be detected through non-invasive tests like carotid Intima Media Thickness (cIMT), Ankle brachial index (ABI) and flow-mediated dilation (FMD) [4, 5].

Studies in diabetic patients suggest as non-invasive tool to predicting atherosclerosis risk, the measuring of accumulation of AGEs in skin using fluorescence techniques (skin autofluorescence (SAF)). It has been observed that there are high levels of fluorescence in skin in patients with type 2 diabetes compared to healthy subjects and it is also directly related with the presence or development of microvascular complications [6].

### OBJECTIVE

To study the association between AGEs and sRAGE levels with cardiovascular risk factors in obese and non-obese newly diagnosed type 2 diabetic patients.

### MATERIAL AND METHODS

We conducted a cross-sectional study in subjects with type 2 diabetes mellitus of recent diagnosis, by means of a glucose tolerance test according to the ADA criteria (ages 35-65). We studied two groups, one with obesity (n=40) and other with normal weight (n=40). We measured somatometric variables, SBP, DBP, glucose, HbA1c, lipid profile, insulin, HOMA-IR, serum AGEs, ICAM-1, VCAM-1, 8-oxo-dG, MDA and, sRAGE. We also measured carotid intima-media thickness (cIMT) and flow-mediated dilation (FMD) by ultrasound.

### RESULTADOS


We studied 80 patients and we divided them in two groups, normal weight (40 patients) and obese (40 patients) with average age: 48±7.3 years old.

CHARACTERISTIC	NORMAL WEIGHT		OBESSE		$T^*/U^1/X^2$	P
	n=40	n=40				
<b>Demographic and anthropometric characteristics</b>						
Age (years)*	50±15	49.2±9.9	0.442	0.7*		
Gender <sup>2</sup>						
Women n (%)	27 (67)	28 (70)	0.483	0.3 <sup>2</sup>		
Men n (%)	13 (33)	12 (30)				
Weight (kg)	64±16	88.5±31.5	-7.108	<0.0001 <sup>1</sup>		
Size(m)	1.63±0.17	1.545±0.205	1.601	0.6*		
BMI (Kg/m <sup>2</sup> )	22.97±2.73	41.7±11.7	-7.706	<0.0001 <sup>1</sup>		
Systolic blood pressure (mmHg)	120±7	124±6	-1.520	0.1 <sup>1</sup>		
Diastolic blood pressure (mmHg)	76±8	78±7	-0.937	0.7*		
<b>BIOCHEMICAL VARIABLES</b>						
Glucose (mg/dl)	140.9±40.4	144.6±47.4	-0.372	0.6*		
HbA1c (%)	6.6±1.6	7.6±1.3	-1.719	0.4*		
Triglycerides(mg/dl)	198.15±98.2	234.3±150.8	-1.591	0.2*		
Cholesterol(mg/dl)	213.1±88.1	220.6±72.6	-2.902	<0.004 <sup>1</sup>		
HDL-C(mg/dl)	66.6±19.6	60.2±10.3	-0.785	0.5*		
LDL-C(mg/dl)	106.2±38.6	114.95±26.5	-2.522	<0.01 <sup>1</sup>		
VLDL-C (mg/dl)	39.6±19.6	46.85±30.15	-1.634	0.14*		
ICAM-1 (ng/mL)	224.6±36.1	278.5±65.9	-3.714	<0.0001 <sup>1</sup>		
VCAM-1 (ng/mL)	623.9±116.6	764.6±174.5	-3.714	<0.0001 <sup>1</sup>		
8-oxo-dG (nM)	52.7±8.3	66.91±17.4	-3.993	<0.0001 <sup>1</sup>		
MDA (nmol/mL)	818.5 ± 519.2	1635.9 ± 1017.7	-3.719	<0.0001 <sup>1</sup>		
Insulin (uU/ml)	6.8±2.7	9.8±2.9	-3.714	<0.0001 <sup>1</sup>		
HOMA- IR	2.4±1.4	3.4±1.2	-3.214	<0.001 <sup>1</sup>		
TOTAL AGES (UA)	938.7±455.8	1302.3±611.9	-4.369	<0.0001 <sup>1</sup>		
CML (ng/mL)	14.7±6.1	22.7±13.9	-5.350	<0.0001 <sup>1</sup>		
CML-NY (u/mL)	12.0±2.5	16.2±4.6	-4.470	<0.0001 <sup>1</sup>		
sRAGE (pg/mL)	857.5±358.2	1197.9±404.1	-3.714	<0.0001 <sup>1</sup>		
<b>CARDIOVASCULAR RISK CHARACTERISTICS</b>						
Carotid intima media thickness (cIMT) (mm)	0.9±0.25	1.1±0.21	-3.205	<0.001 <sup>1</sup>		
Flow-mediated dilation in the brachial artery (FMD) (%) <sup>2</sup>	24.6±14.8	15.4±10.9	558.0	0.02 <sup>2</sup>		
Rigidity index	3.2±2.2	4.2±2.4	-2.608	<0.009 <sup>1</sup>		
Ankle brachial index (AAI)	0.99±0.08	0.96±0.07	1.113	0.6*		
Skin autofluorescence(UA)	2.16±0.47	2.19±0.28	0.096	0.2*		
Framingham Risk Score (%) <sup>2</sup>	7.4±3.9	8.02±3.0	23.4	0.1 <sup>2</sup>		
<b>DIETARY VARIABLES</b>						
Dietary AGES (KU)	9623.1±923.6	10,776.2±1121.9	-5.02	<0.015*		
Food Energy(Kcal)	2548.9±267.4	3484.2±347.7	12.5	<0.0001*		
Proteins	110.1±21.91	137.3±79.2	-0.010	0.1 <sup>1</sup>		
Carbohydrates	339.7±48.1	257.3±187.9	-2.539	<0.011 <sup>1</sup>		
Lipids	83.0±31.2	282.9±404.4	-6.865	<0.0001 <sup>1</sup>		

Table 2  
Factors associated with Skin autofluorescence

TOTAL GROUP			
SIGNIFICANT VARIABLES	$\beta$	T	P
Carotid intima media thickness (cIMT)	-0.401914	-3.59827	<0.0001
HOMA-IR	0.337958	3.03003	<0.001
sRAGE	0.523646	3.01640	<0.001
Ankle brachial index (AAI)	0.231512	2.76447	<0.001
BMI	-0.163788	-1.98921	<0.05
<b>NO SIGNIFICANT VARIABLES</b>			
Carotid intima media thickness (cIMT)	0.179603	1.77489	0.08
Framingham Risk Score	0.145122	1.72310	0.09
8-oxo-dG	-0.432643	-1.65916	0.1
HDL-C	-0.155347	-1.65689	0.1
Cholesterol	0.127630	1.31372	0.2
ICAM-1	0.364165	1.18105	0.2
<b>OBSESE GROUP</b>			
Framingham Risk Score	0.72309	3.02838	<0.005
8-oxo-dG	-2.33385	-2.51903	<0.01
Carotid intima media thickness (cIMT)	-0.35325	-2.39460	<0.02
ICAM-1	2.42539	2.31482	<0.03
<b>NO SIGNIFICANT VARIABLES</b>			
sRAGE	0.39173	1.41420	0.2
HOMA-IR	0.18898	1.22232	0.2
Rigidity index	-0.16816	-1.21967	0.2
Age	-0.22614	-0.92035	0.4
<b>NORMAL WEIGHT GROUP</b>			
Carotid intima media thickness (cIMT)	-0.489868	-6.75648	<0.00001
HOMA-IR	0.434311	4.30263	<0.0001
Ankle brachial index (AAI)	0.186815	2.99637	<0.005
sRAGE	0.298611	2.75265	<0.001
LDL-C	0.133326	2.14750	<0.04
<b>NO SIGNIFICANT VARIABLES</b>			
8-oxo-dG	-0.182463	-1.89383	0.07
Dietary AGES	0.100727	1.69514	0.1
HDL-C	-0.089001	-1.24935	0.2

Graphic 1  
Correlation between Skin autofluorescence and cIMT in the Total Group



$p = 0.7107; r^2 = 0.0018$

### Conclusion

The results show association of serum AGEs with ICAM-1 and HOMA-IR and strong association of sRAGE with VCAM-1, ICAM-1, MDA and cIMT.

### REFERENCES

- Goldin, A., Beckman, J.A., Schmidt, A.M. & Creager, M.A. (2006). Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation* 114:597–605.
- Lutgers, H.L., Graaff, R., De Vries, R., Smit, A.J. & Dullaart, R.P. (2010). Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease. *Eur J Clin Invest*. 40:812-7.
- Mackenzie, I.S., Wilkinson, I.B. & Cockcroft, J.R. (2002). Assessment of arterial stiffness in clinical practice. *Q J Med* 95:67–74.
- American Heart Association. (2010). ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. November 12.
- Arrebola-Moreno, A., Laclaustra, M., Kaskila, J.C., (2012). Evaluación no invasiva de la función endotelial en la práctica clínica. *RevEspCardiol*. 65(1):80–90.
- Lutgers, H.L., Graaff, R., Links, T.P., Ubink-Veltmaat, L.J., Bilo, H.J., Gans, R.O. & Smit, A.J. (2006). Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. *Diabetes Care*. 29:2654–2659.

Supported by Grant of FOMIX-GTO (GTO-2012-C03-195211)